• ქართული
  • English
  • GSK expects shingles drug sales to exceed $1.3 billion after 'fantastic' quarter

    GlaxoSmithKline forecast 2019 sales of its fast-growing shingles vaccine Shingrix to be “significantly” more than 1 billion pounds ($1.31 billion) on Wednesday as a drop in the British drugmaker’s free cash flow weighed on its shares.

    Market Quotes by TradingView